SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Spargo B, Seymour A, Ordonez N. Renal biopsy pathology with diagnostic and therapeutic implications. New York: John Wiley & Sons; 1980.
  • 2
    Ponticelli C, Moroni G. Renal biopsy in lupus nephritis: what for, when and how often? Nephrol Dial Transplant 1998; 13: 24524.
  • 3
    Baldwin D, Gluck M, Lowenstein J, Gallo G. Lupus nephritis: clinical course as related to morphologic forms and their transitions. Am J Med 1977; 62: 1230.
  • 4
    Churg J, Sobin L. Lupus nephritis. In: Renal disease: classification and atlas of glomerular diseases. Tokyo: Igati-Shoim; 1982. p. 12749.
  • 5
    Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, et al. Prognostic factors in lupus nephritis: contribution of renal histologic data. Am J Med 1983; 75: 38291.
  • 6
    McLaughlin J, Gladman D, Urowitz M, Bombardier C, Farewell V, Cole E. Kidney biopsy in systemic lupus erythematosus. II. Survival analyses according to biopsy results. Arthritis Rheum 1991; 34: 126873.
  • 7
    Schwartz M, Lan S, Bernstein J, Hill G, Holley K, Lewis E. Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Am J Kidney Dis 1993; 21: 3747.
  • 8
    Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 6149.
  • 9
    Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP. The pathogenesis and prognosis of lupus nephritis: information from repeat renal biopsy. Semin Arthritis Rheum 1993; 23: 13548.
  • 10
    Donadio J, Hart G, Bergstralh E, Holley K. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995; 4: 10915.
  • 11
    Jennette C, Iskandar S, Dalldorf F. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int 1983; 24: 37785.
  • 12
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 17788.
  • 13
    Schwartz MM, Lan SP, Bonsib SM, Gephardt GN, Sharma HM. Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis. Am J Kidney Dis 1989; 13: 27383.
  • 14
    Moroni G, Banfi G, Ponticelli C. Clinical status of patients after 10 years of lupus nephritis. Q J Med 1992; 84: 6819.
  • 15
    Neumann K, Wallace DJ, Azen C, Nessim S, Fichman M, Metzger AL, et al. Lupus in the 1980s. III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum 1995; 25: 4755.
  • 16
    Sloan RP, Schwartz MM, Korbet SM, Borok RZ. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis: Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 1996; 7: 299305.
  • 17
    Pasquali S, Banfi G, Zucchelli A, Moroni G, Ponticelli C, Zucchelli P. Lupus membranous nephropathy: long-term outcome. Clin Nephrol 1993; 39: 17582.
  • 18
    Adler SG, Johnson K, Louie JS, Liebling MR, Cohen AH. Lupus membranous glomerulonephritis: different prognostic subgroups obscured by imprecise histologic classifications. Mod Pathol 1990; 3: 18691.
  • 19
    Chan T, Li F, Hao W, Tang C, Lai K. Sequential use of cyclophosphamide and azathioprine in the treatment of membranous lupus nephropathy (MLN) with nephrotic syndrome. Lupus 1998; 7: 117.
  • 20
    Huong DL, Papo T, Beaufils H, Wechsler B, Bletry O, Baumelou A, et al. Renal involvement in systemic lupus erythematosus: a study of 180 patients from a single center. Medicine (Baltimore) 1999; 78: 14866.
  • 21
    Donadio JV Jr. Treatment of membranous nephropathy in systemic lupus erythematosus. Nephrol Dial Transplant 1992; 7: 97104.
  • 22
    Gladman DD, Urowitz MB, Cole E, Ritchie S, Chang CH, Churg J. Kidney biopsy in SLE. I. A clinical-morphologic evaluation. Q J Med 1989; 73: 112533.
  • 23
    Leaker B, Fairley KF, Dowling J, Kincaid-Smith P. Lupus nephritis: clinical and pathological correlation. Q J Med 1987; 62: 16379.
  • 24
    Radhakrishnan J, Kunis CL, D'Agati V, Appel GB. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994; 42: 14754.
  • 25
    Banfi G, Moroni G, Maccario M. Treatment of membranous lupus nephritis. Lupus 1998; 7: 76.
  • 26
    Moroni G, Maccario M, Banfi G, Quaglini S, Ponticelli C. Treatment of membranous lupus nephritis. Am J Kidney Dis 1998; 31: 6816.
  • 27
    Caccavo D, Lagana B, Mitterhofer AP, Ferri GM, Afeltra A, Amoroso A, et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 1997; 40: 2735.
  • 28
    Ponticelli C, Villa M. Does cyclosporin have a role in the treatment of membranous nephropathy? Nephrol Dial Transplant 1999; 14: 2325.
  • 29
    Gruppo Italiano per 10 Studio della Nefrite Lupica (GISNEL). Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after diagnosis. Am J Kidney Dis 1996; 19: 4739.
  • 30
    Cameron JS, Turner DR, Ogg CS, Williams DG, Lessof MH, Chantler C, et al. Systemic lupus with nephritis: a long-term study. Q J Med 1979; 48: 124.
  • 31
    Hricik DE, Chung-Park M, Sedor JR. Glomerulonephritis. N Engl J Med 1998; 339: 88899.
  • 32
    Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329: 859.
  • 33
    Hay NM, Bailey RR, Lynn KL, Robson RA. Membranous nephropathy: a 19 year prospective study in 51 patients [published erratum appears in N Z Med J 1993;106:22]. N Z Med J 1992; 105: 48991.
  • 34
    Glassock RJ. The therapy of idiopathic membranous glomerulonephritis. Semin Nephrol 1991; 11: 13847.
  • 35
    Lewis EJ. Idiopathic membranous nephropathy: to treat or not to treat? [editorial; comment]. N Engl J Med 1993; 329: 1279.
  • 36
    Marx BE, Marx M. Prognosis of idiopathic membranous nephropathy: a methodologic meta-analysis. Kidney Int 1997; 51: 8739.
  • 37
    Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. N Engl J Med 1979; 301: 13016.
  • 38
    Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989; 320: 813.
  • 39
    Brown JH, Douglas AF, Murphy BG, Hill CM, McNamee PT, Nelson WE, et al. Treatment of renal failure in idiopathic membranous nephropathy with azathioprine and prednisolone. Nephrol Dial Transplant 1998; 13: 4438.
  • 40
    Ahuja M, Goumenos D, Shortland JR, Gerakis A, Brown CB. Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy? Am J Kidney Dis 1999; 34: 5219.
  • 41
    Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9: 44450.
  • 42
    Branten AJ, Reichert LJ, Koene RA, Wetzels JF. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. Q J Med 1998; 91: 35966.
  • 43
    Sterling CM, Simpson K, Boulton-Jones JM. Immunosuppression and outcome in idiopathic membranous nephropathy. Q J Med 1998; 91: 15964.
  • 44
    Geddes CC, Cattran DC. The treatment of idiopathic membranous nephropathy. Semin Nephrol 2000; 20: 299308.
  • 45
    Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997; 29: 1939.
  • 46
    Imperiale TF, Goldfarb S, Berns JS. Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials. J Am Soc Nephrol 1995; 5: 15538.
  • 47
    Falk RJ, Hogan SL, Muller KE, Jennette JC, The Glomerular Disease Collaborative Network. Treatment of progressive membranous glomerulopathy: a randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. Ann Intern Med 1992; 116: 43845.
  • 48
    Reichert LJ, Huysmans FT, Assmann K, Koene RA, Wetzels JF. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann Intern Med 1994; 121: 32833.
  • 49
    Wang AY, Li PK, Lai FM, Chow KM, Szeto CC, Leung CB, et al. Severe bone marrow failure associated with the use of alternating steroid with chlorambucil in lupus membranous nephropathy in Chinese. Lupus 2001; 10: 2958.
  • 50
    Miller G, Zimmerman R 3rd, Radhakrishnan J, Appel G. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000; 36: 2506.
  • 51
    Cross J, Jayne D. Mycophenolate mofetil in lupus nephritis. Lupus 2000; 9: 64750.